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The influence of ifosfamide scheduling on acute
nephrotoxicity in children
MW English, R Skinner, ADJ Pearson, L Price, R Wyllie and AW Craft
Sir James Spence Institute of Child Health, The Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP, UK
Summary Nephrotoxicity is a significant problem in children after treatment with ifosfamide. Acute changes in renal function were compared
in 16 children receiving 9 g m-2 of ifosfamide as a 72-h continuous infusion on one occasion and, on another course, divided into three 1-h
infusions on consecutive days. Subclinical acute nephrotoxicity was demonstrated with both schedules, but there were no significant
differences in severity.
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Subclinical renal damage has been reported in most children
treated with ifosfamide (Skinner et al, 1990; Heney et al, 1991),
and in some series between 20% and 40% of children have
required some form of mineral replacement therapy because of
inappropriate renal tubular loss of phosphate and bicarbonate
(Skinner et al, 1990; Caron et al, 1992; De Schepper et al, 1993).
Renal failure may occur acutely and prevent the delivery of
planned chemotherapy, howeverit is more often achronic problem
with severely affected children suffering from hypophosphataemic
rickets, renal tubular acidosis and occasionally nephrogenic
diabetes insipidus. Impairment of growth may result from renal
tubular acidosis and rickets (De Schepper et al, 1991; Rossi et al,
1992; Skinner et al, 1992). Higher cumulative dose of ifosfamide,
younger patient age at treatment (Suarez et al, 1991; Skinner et al,
1992; Al Sheyyab et al, 1993; De Schepper et al, 1993), prior
nephrectomy and pre-existing renal impairment, including that
caused by prior or concomitant treatment with cisplatin, have all
been reported as being associated with an increased risk of ifos-
famide-induced nephropathy (Pratt et al, 1991; Suarez et al, 1991;
Caron et al, 1992; Skinner et al, 1992; Al Sheyyab et al, 1993; De
Schepper et al, 1993), Marina et al, 1993; Tournade, 1993; Rossi et
al, 1994a,b).
A further possible risk factor is the method of administration of
the drug. Schedules ofadministration in children have varied from
short infusions over 15 min to continuous infusion over 3 or more
days. One study in adults reported less nephrotoxicity after contin-
uous infusion rather than bolus administration of ifosfamide, but
the differences were not statistically significant (Antman et al,
1989). Nephrotoxicity has been documented after all schedules of
ifosfamide, and a detailed review found no clear evidence that any
schedule showed a significant difference in nephrotoxicity
(Skinner et al, 1993). Although both acute and chronic changes
have been shown after the administration of ifosfamide, so far
there have been no reports oflongitudinal studies relating the two.
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Ifosfamide is a prodrug that metabolized in the liver by the
cytochrome P-450 system, and administration by a short infusion
may saturate metabolizing capacity, which would provide an
explanation for different toxicities between schedules. This report
describes a comparison ofthe acute changes in renal function seen
after the administration of 6 or 9 g m-2 ifosfamide as a continuous
infusion (CI) over 72 h or divided into three 1-h infusions (SI) on
consecutive days.
METHODS
Patients
All patients treated at this centre between June 1991 and June
1994 with protocols that included ifosfamide, but no other nephro-
toxic chemotherapy, were entered into a prospective investigation
ofchanges in renal function during ifosfamide treatment. In order
to investigate the pharmacokinetics of ifosfamide given as a CI or
SI, patients who usually received ifosfamide as a CI over 72 h
received it divided into three 1-h infusions on three consecutive
days, and patients who usually received it as a SI over 1 h on three
consecutive days received it as a CI over 72 h.
Twenty children entered the study of the prospective investiga-
tion ofrenal function following ifosfamide. Difficulty incollecting
urine orbloodbefore or afterthe course ofifosfamidegiven forthe
pharmacokinetic study meant that only 16 patients (five female)
could be investigated in this study. Their ages ranged from
0.9-12.5 years, mean 6.3 years. Underlying diagnoses are shown
in Table 1. No patient had received prior or concurrent treatment
with cisplatin, carboplatin, radiotherapy to a field involving the
kidney or prior nephrectomy. No patient received nephrotoxic
antibiotics while the ifosfamide was administered. One patient
received a course of intravenous vancomycin 7 days after each
course ofifosfamide that was studied.
Drug administration
Nine of the children received the SI before the CI, and seven
received the CI before the SI. Patients received 9 g m-2 ifosfamide
over 72 h either as a continuous infusion or as three daily 1-h infu-
sions. Concurrent with ifosfamide 3000 ml m-2 offluid containing
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Table 1 Patient characteristics
Patient Agea Sex Diagnosis Cumulative doseb Cumulative
no. (years) before short dosec before
infusion course continuous
(g m-2) infusion course
(g m-2)
1 1.9 F Triton tumour 36 27
2 8.5 F Rhabdo 144 135
3 1.0 M PNET 9 0
4 3.8 F Ewing's 6 0
5 11.4 M Thymoma 9 0
6 10.0 M Ewing's 27 18
7 12.5 M MEC 36 63
8 8.4 M Rhabdo 9 18
9 0.9 M Schwannoma 45 54
10 4.1 M Rhabdo 45 63
11 6.7 F Rhabdo 18 27
12 5.0 M Rhabdo 18 27
13 7.4 M Rhabdo 135 144
14 2.2 M Rhabdo 63 81
15 5.7 F Rhabdo 18 27
16 9.9 M Angiosarcoma 9 0
aMean age (years) 6.25 (0.9-12.5). bMean cumulative dose 39 (6-144) g m-2.
cMean cumulative dose 43 (0-144) g mr3. Rhabdo, rhabdomyosarcoma;
PNET, primitive neuroectodermal tumour; MEC, malignant epithelioid
carcinoma. All patients received 9 g m-2 ifosfamide per course except for
patient 4 who received 6 g m-2 per course.
3 g m-2 mesna were administered each day. In addition, when ifos-
famide was infused over 1 h, a bolus of 1.2 g m-2 mesna was given
at the start of treatment on day 1, and those receiving ifosfamide
by continuous infusion had an additional 12 h of intravenous
hydration with 1.5 g m-2 mesna in the hydration fluid after the
ifosfamide finished. Patient 4 received only 6 g m-2 ifosfamide per
course over 3 days, and the mesna dose was reduced by an equiva-
lent amount. Other cytotoxic drugs that the patients received
included etoposide or vincristine and doxorubicin or vincristine
and actinomycin.
Measures of nephrotoxicity
We have previously described a protocol to assess glomerular and
proximal and distal renal tubular function (Skinner et al, 1991).
Serum creatinine (S Creat) was used because of the practical and
ethical difficulties of performing three plasma [51Cr]EDTA clear-
ances within 3 weeks to assess glomerular function when not clin-
ically necessary. Proximal renal tubular function was assessed by
measuring serum carbon dioxide (SCO2), the renal tubular
threshold for phosphate (TmpIGFR), fractional excretion of
glucose (FE gluc) and the urine retinol binding protein to urine
creatinine ratio (URBP:C). Distal renal tubular function was
assessed by changes in urine pH and osmolality (U osmo). Global
renal tubular function was assessed by measuring the ratios ofthe
urine concentrations of the following-substances to urine creati-
nine: protein (UProt:C), retinol binding protein (URBP:C), alka-
line phosphatase (UALP:C), alanine aminopeptidase (UAAP:C),
lactic dehydrogenase (ULDH:C) and N-acetylglucoseaminidase
(UNAG:C). These measurements were performed before and at
1 and 18 days after completing chemotherapy.
Analysis of results
Changes in renal function after CI and SI at I or 18 days after
completion of chemotherapy were compared with the pretreatment
results. Wilcoxon's signed-rank test was used to testthe significance
ofthe changes seen after each schedule.
Table 2 Changes from before to 5 days after Cl and SI of ifosfamide
Parameter Continuous infusion (Cl) Short infusion (SI)
Median before Cl Median change Median before SI Median change
(range) (range) (range) (range)
S Creat 50.5 -1.0a 49.5 +2.0
(1mol 1-') (26-62) (-13 to +7) (33-64) (-15 to + 14)
Serum carbon dioxide 22 _2.5b 22 -2.0b
(mmol 1-') (17-25) (-8 to +2) (15-26) (-7 to +5)
TmP/GFR 1.29 -0.41b 1.28 -0.35b
(mmol 1-') (0.71-1.66) (-0.92 to +0.07) (0.73-1.67) (-0.96 to 0.07)
URBP:C 38 +568 67 +335b
(,ug mmol-') (7.7-83 333) (-82371 to +321774) (8-315 789) (-45 to +11403)
FE gluc 0.075 +0.2a 0.03 +0.1b
(%) (0.01-3.69) (-3.38 to 2.9) (0.01-4.28) (-0.2 to +8.58)
Urine pH 6.2 +0.9 6.2 +0.8a
(5.0-7.4) (-0.9 to 3.1) (4.8-7.3) (-1.3 to +2.2)
UProt:C 48.5 +60a 38 +82b
(mg mmol-1) (11-250) (-137 to +360) (12-250) (+29 to +397)
UNAG:C 0.635 +5.91b 0.495 +2.46b
([L mmol-1) (0.09-36.58) (+1.21 to +59.12) (0.13-26) (+0.24 to +48.81)
UAAP:C 2.79 +8.89b 2.85 +1.4
([L mmol-1) (0.78-53.74) (+2.69 to +54.75) (0.57-26.54) (-8.74 to +16.02)
ULDH:C 4.03 +13.83b 4.13 +5.21a
(t mmol-1) (0.71-44.71) (-0.94 to +131.4) (1.11-23.86) (-3.3 to +94.69)
UAKP:C 0.635 +0.97a 0.45 +0.14
([t mmol-1) (0.07-2.71) (-0.54 to +4.26) (0.07-2.95) (-3.65 to +1.83)
ap <0.05. bp <0.01.
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The patients were divided into two groups, those who had
received the CI before the SI and those who had received the SI
before the CI. A 2 x 2 crossover analysis was performed and the
groups were examined for evidence of (1) a treatment effect, i.e.
was one schedule more nephrotoxic than the other? (2) a period
effect, i.e. did the orderofadministration affect the results? and (3)
a treatment-period interaction, i.e. were the treatment and period
effects more than simply additive (Armitage and Berry 1987)?
The study was approved by The Joint University of Newcastle
upon Tyne and Newcastle Hospitals Ethical Committee. Informed
consent was obtained from the parents and, when appropriate, the
patients.
RESULTS
Early changes 1 day after treatment
These results are shown in Table 2. There were significant falls in
the SCO2 and Tmp/GFR and significant rises in the FE gluc, the
urine pH, the UNAG:C, ULDH:C and UProt:C after both the CI
and the SI. There was a significant rise after the CI schedule but
not the SI schedule for the UAAP:C. There were significant rises
after the SI but not the CI schedule for UALP:C and URBP:C.
There was a significant reduction in the S creat after the CI but not
after the SI. There was a significant fall in U osmo after both
schedules; this is to be expected because ofthe hydration regimen
and is not reported.
Late changes 18 days after treatment
The above changes had largely resolved 18 days after completion
of treatment, and the only significant differences were elevations
seen in FE gluc (P = 0.01), URBP:C (P = 0.031) and UNAG:C (P
= 0.046) after the CI but not after the SI and a reduction in the
serum carbon dioxide after the SI (P = 0.021) but not the CI.
Comparison between schedules
No significant treatment effect, period effect or treatment-period
interaction was demonstrated for either the SI or the CI. As shown
in Table 2, both schedules had very similar effects on measures of
subclinical nephrotoxicity. The small numbers in this study mean
that the power of detecting an important difference in the parame-
ters measured is low. For example, the power of detecting a 25%
difference in Tm /GFR between the two schedules at a-level 0.05
p
is only 44%. Based on the differences seen over the first two
courses of treatment in the patients in the prospective study, 96
subjects undergoing paired studies would be required to detect this
with a power of 80%.
DISCUSSION
The administration of ifosfamide either as a CI or a SI caused
significant short-term changes in renal function. This was most
striking for the SCO2, Tm/GFR, UNAG:C, ULDH:C, UProt:C and
FE gluc. There were no important changes in the S creat after
either schedule. The FE gluc, URBP:C and UNAG:C were still
elevated 21 days after the CI, and the SCO2 was lower 21 days after
the SI. Using a crossover analysis, there was no significant differ-
ence in the nephrotoxicity observed when ifosfamide was adminis-
tered either as a continuous infusion or three separate 1-h infusions.
It is now apparent that both schedules cause significant changes in
measures ofsubclinicalrenal damage. Considerably largernumbers
ofpatients would need to be entered into a study to have sufficient
power to confirm a statistically significant difference between the
schedules, however the similarity of the changes after the CI and
the SI suggest thatclinically important differences are unlikely. It is
known that ifosfamide causes cumulative damage (Heney et al,
1991; Caron et al, 1992; Al Sheyyab et al, 1993) which could
confound the results, however the cumulative dose before each
schedule was very similar and no treatment-period interaction was
demonstrated, although again the numbers are small.
Both RBP and B2 microglobulin have been found to be sensitive
measures of ifosfamide-induced renal tubular damage (Al
Sheyyab et al, 1993; De Schepper et al, 1993). Some patients were
already on treatment when this study started and had already
received large cumulative doses of ifosfamide. These heavily
pretreated patients demonstrated abnormalities in the baseline
studies especially in the URBP:C. This pre-existing damage may
explain why this very sensitive test was not a more discriminating
test for acute renal damage between the ifosfamide schedules that
were studied. Ifosfamide is a prodriug and it is thought that its
nephrotoxic metabolites may include chloracetaldehyde which is
produced in equimolar quantities with the dechlorethylated
metabolites (Skinner et al, 1993). The patients reported in this
paper have all had pharmacokinetic and metabolic studies of ifos-
famide performed. These have been reported as studies of ifos-
famide administered as a continuous infusion (Boddy et al, 1993)
and studies of intra-individual variation in metabolism (Boddy et
al, 1994). A comparison ofthe metabolism ofifosfamide adminis-
tered either as short or as continuous infusions showed that there
was atrend forreducedproduction ofdechlorethylated metabolites
following short infusions (Boddy et al, 1995). A negative correla-
tion between theproduction ofdechlorethylated metabolites over6
months during ifosfamide treatment and renal damage 1 and 6
months after the completion of treatment has been observed
(Boddy etal, 1996). This study also observed no significant differ-
ence in nephrotoxicity between ifosfamide administered as a SI or
a CI. There is overlap between 12 patients in that study and those
reported in the present study. The comparisons of nephrotoxicity
between SI and CI were made between courses when pharmacoki-
netic studies were performed, and these could be separated by
several other courses of treatment. Therefore the hypothesis that
ifosfamide schedule is related to nephrotoxicity was tested sepa-
rately and is reported in the current paper.
The present study examined acute changes in renal function
following the administration of ifosfamide. There is evidence that
renal damage occurs early on in treatment with ifosfamide and is
progressive (Heney et al, 1991; Caron et al, 1992; Al Sheyyab et
al, 1993), but acute changes in renal function following one course
of treatment have not yet been related to long-term renal damage.
This study compares the nephrotoxicity of different schedules of
ifosfamide in the same patients. In a phase II study in adults, the
schedule ofifosfamide was changed from 2 g m-2 over 4 h on four
consecutive days to 8 g m-2 by continuous infusion over 4 days in
an attempt to reduce toxicity (Antman et al, 1989). The authors
noted a reduction in overall toxicity (especially encephalopathy)
with continuous infusions but no difference in the fall in serum
bicarbonate concentration between schedules.
This study confirms that ifosfamide given as either a CI or a SI
does cause acute changes in renal function; however it shows no
evidence for differing severity of acute subclinical nephrotoxicity
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between the schedules. The small number of subjects means that
there is the possibility ofa 1-error and that there really is a statisti-
cally significant difference between the schedules, however the
evidence presented here suggests that this is unlikely to be ofclin-
ical importance. Future studies using ifosfamide should investi-
gate reducing the total dose of ifosfamide and trying to predict
those at increased risk of ifosfamide-induced renal damage. If
scheduling of the drug is altered in an attempt to reduce toxicity
then it should be done in a prospective, randomized trial that
includes both toxicity and efficacy after treatment as end points.
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